Key Summary: On April 1, 2024, Stavros G. Vizirgianakis (5.04%) announced plans to engage with management and the board. On May 7, 2024, Stavros Vizirgianakis (5.04%) joined the board, filling a vacancy and becoming Chair, following a letter agreement with the company. On April 5, 2024, Strategos Fund/Archon Capital Management (9.9%) announced its ongoing dialogue with the Board and management team. On May 7, 2024, Stavros Vizirgianakis reached a letter agreement with the company and pursuant to it, the company appointed Mr. Vizirgianakis to its BoardMarket Cap: $57 million | Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally.
On April 1, 2024, Stavros G. Vizirgianakis (5.04%) stated that he plans to engage with management and the board to discuss current and future challenges, conducting a strategic review to address shareholder concerns and enhance value creation. Source
On April 5, 2024, Strategos Fund/Archon Capital Management (9.9%) announced its ongoing dialogue with the Board and management team to explore avenues for enhancing shareholder value, such as bolstering the Board with highly qualified directors. Source
On May 7, 2024, Stavros Vizirgianakis reached a letter agreement with the company and pursuant to it, the company appointed Mr. Vizirgianakis to its Board, filling a vacancy left by Andrew Makrides' resignation and retirement. Additionally, Mr. Vizirgianakis was named Chair of the Board.
Comments